系统性红斑狼疮患者骨坏死发生率的变迁:聚焦免疫抑制剂与糖皮质激素
该回顾性研究纳入1986至2015年新诊断并住院接受初始大剂量糖皮质激素治疗的185例SLE患者共740个关节,按钙调磷酸酶抑制剂引入前后分为既往组116例与近期组69例。近期组糖皮质激素剂量显著低于既往组,骨坏死发生率亦显著降低(26.4% vs 41.0%)。
要点
- 近期组骨坏死发生率26.4%,显著低于既往组的41.0%。
- 近期组膝关节骨坏死发生率25.4%,显著低于既往组的46.6%。
- 免疫抑制剂引入后糖皮质激素用量减少,骨坏死发生率随之下降。
核心结论
- SLE患者糖皮质激素相关骨坏死发生率下降,与免疫抑制剂引入后糖皮质激素用量减少相关。
研究设计与样本
- 回顾性登记1986至2015年新诊断并住院接受初始大剂量糖皮质激素治疗的185例SLE患者共740个关节。
- 按免疫抑制剂使用趋势分组:1986至1999年钙调磷酸酶抑制剂引入前治疗的116例为既往组,2000至2015年治疗的69例为近期组。
主要发现
- 两组患者特征(年龄、性别、住院时器官病变、补体、抗DNA抗体、抗凝药与抗脂药使用频率)相似。
- 近期组糖皮质激素剂量显著低于既往组:最高日剂量45.7 vs 59.0 mg/day,每公斤体重剂量0.88 vs 1.16 mg/day/kg,3个月累积剂量3118 vs 3985 mg。
- 近期组骨坏死发生率显著低于既往组(26.4 vs 41.0%)。
- 近期组膝关节骨坏死发生率显著低于既往组(25.4 vs 46.6%)。
关键数值与推荐
- 近期组最高日糖皮质激素剂量45.7 mg/day,既往组59.0 mg/day。
- 近期组每公斤体重糖皮质激素剂量0.88 mg/day/kg,既往组1.16 mg/day/kg。
- 近期组3个月累积糖皮质激素剂量3118 mg,既往组3985 mg。
- 近期组骨坏死发生率26.4%,既往组41.0%。
- 近期组膝关节骨坏死发生率25.4%,既往组46.6%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to investigate transitional changes in the incidence of glucocorticoid-associated osteonecrosis in SLE patients, with a focus on immunosuppressive agent and glucocorticoid consumption. METHODS: We retrospectively registered 185 SLE patients with 740 joints, who were newly diagnosed and hospitalized for initial high-dose glucocorticoid therapy from 1986 to 2015. Immunosuppressive agent, glucocorticoid dose, age, sex, organ lesion at hospitalization, complement (C3, C4, CH50) and anti-DNA antibody before initial glucocorticoid therapy, the frequency of use of anticoagulant and antilipidemic drugs, and incidence of osteonecrosis were documented. RESULTS: Based on trends in immunosuppressive agent use, 116 patients treated from 1986 to 1999, before calcineurin inhibitors were introduced, comprised the past group, and 69 patients treated from 2000 to 2015 comprised the recent group. Patient characteristics (age, sex and organ lesion at hospitalization, complement, anti-DNA antibody, the frequency of use of anticoagulant and antilipidemic drugs) were similar between groups. Glucocorticoid doses were significantly lower in the recent group than in the past group (highest daily glucocorticoid dose, 45.7 vs 59.0 mg/day, respectively; dose per weight, 0.88 vs 1.16 mg/day/kg, respectively; and cumulative dose at 3 months, 3118 vs 3985 mg). The incidence of osteonecrosis was significantly lower in the recent group than in the past group (26.4 vs 41.0%, respectively), particularly in the knee (25.4 vs 46.6%, respectively). CONCLUSION: The incidence of glucocorticoid-associated osteonecrosis in SLE patients decreased in association with a decrease in glucocorticoid administration after introduction of immunosuppressant agents.
引用
- Nawata K, Nakamura J, Ikeda K, et al. Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus patients: focus on immunosuppressant agents and glucocorticoids. Rheumatology (Oxford). 2018. PMID: 29462407. doi:10.1093/rheumatology/key009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。